STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-188)	LORIGERLIMAB
PRONUNCIATION	lor” i jer’ li mab
THERAPEUTIC CLAIM	Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin, anti-(human programmed cell death protein 1) (human-Mus musculus clone MG13.78 κ-chain V-J region) fusion protein with peptide linker (GGGSGGGG) fusion protein with immunoglobulin anti-(human cytotoxic T-lymphocyte-associated protein 4) (human clone 4B6 heavy chain V-D-J region) fusion protein with peptide linker (GGCGGG) fusion protein with peptide (synthetic E-coil) fusion protein with immunoglobulin G4 [10-proline,34-tyrosine,36-threonine,38-glutamic acid,de-229-lysine] (human γ4-chain C region C-terminal fragment), disulfide with immunoglobulin anti-(human cytotoxic T-lymphocyte-associated protein 4) (human clone 4B6 κ-chain V-J region) fusion protein with linker peptide (GGGSGGGG) fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus clone MG13.78 heavy chain V-D-J region) fusion protein with peptide linker (GGCGGG) fusion protein with peptide (synthetic K-coil), dimer (Source: CAS)

2. Immunoglobulin G4 scFv-h-CH2-CH3_scFv, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD1, PD-1, CD279)] and anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], chimeric, *Homo sapiens* and humanized monoclonal antibody, tetravalent, bispecific; scFv-h-CH2-CH3, chimeric and *Homo sapiens*, anti-PDCD1 and anti-CTLA4 (1-499) [scFv-V-KAPPA-VH (1-237) [V-KAPPA anti-PDCD1 Musmus/Homsap (*Mus musculus* IGKV3-2*01 (80.8%) -(IGHD) -IGKJ2*01 (91.7%) L124>V (108)/*Homo sapiens* IGKV3D-11*02 (77.7%) -(IGHD) -IGKJ4*01 (100%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1-111) -8 mer triglycyl-seryl-tetraglycyl linker (112-119) -VH anti-CTLA4 (*Homo sapiens* IGHV3-30*01 (93.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (145-152.170-177.216-226)) (120-237)] -E-coil linker (238-271) [6-mer diglycyl-cysteinyl-triglycyl linker (238-243) -28-mer (glutamyl-valyl-dialanyl-cysteinyl-glutamyl-lysyl)-tris(glutamyl-valyl-dialanyl-leucyl-glutamyl-lysyl) E-coil motif (244-271)] -[scFc *Homo sapiens* IGHG4*01 h-CH2-CH3, G4v5 h P10, G4v21 CH2 Y15.1, T16, E18 (hinge 1-12 S10>P (281) (272-283), CH2 M15.1>Y (305), S16>T (307), T18>E (309) (284-393), CH3 (394-498), CHS K2>del (499)) (272-499)] (248''-246')-disulfide with scFv-V-KAPPA-VH, *Homo sapiens* and humanized, anti-CTLA4 and anti-PDCD1 (1'-269') [V-KAPPA anti-CTLA4 (*Homo sapiens* IGKV3-20*01 (99.0%) -IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98)) (1'-108') -8 mer triglycyl-seryl-tetraglycyl linker (109'-116') -VH anti-PDCD1 (*Homo sapiens* IGHV1-46*01 (81.6%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.12] (142-149.167-174.213-224)) (117'-235')] -K-coil linker (236'-269') [6-mer diglycyl-cysteinyl-triglycyl linker (236'-241') -28-mer (lysyl-valyl-dialanyl-cysteinyl-lysyl-glutamyl)-tris(lysyl-valyl-dialanyl-leucyl-lysyl-

glutamyl) K-coil motif (242'-269')]; dimer (279-279'':282-282'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-S cell line, glycoform alfa (Source: WHO pINN list 125)

STRUCTURAL FORMULA

Heavy chain X, X''

```
EIVLTQSPAT  LSLSPGERAT  LSCRASESVD  NYGMSFMNWF  QQKPGQPPKL   50
LIHAASNQGS  GVPSRFSGSG  SGTDFTLTIS  SLEPEDFAVY  FCQQSKEVPY  100
TFGGGTKVEI  KGGGSGGGGQ  VQLVESGGGV  VQPGRSLRLS  CAASGFTFSS  150
YTMHWVRQAP  GKGLEWVTFI  SYDGSNKHYA  DSVKGRFTVS  RDNSKNTLYL  200
QMNSLRAEDT  AIYYCARTGW  LGPFDYWGQG  TLVTVSSGGC  GGGEVAACEK  250
EVAALEKEVA  ALEKEVAALE  KESKYGPPCP  PCPAPEFLGG  PSVFLFPPKP  300
KDTLYITREP  EVTCVVVDVS  QEDPEVQFNW  YVDGVEVHNA  KTKPREEQFN  350
STYRVVSVLT  VLHQDWLNGK  EYKCKVSNKG  LPSSIEKTIS  KAKGQPREPQ  400
VYTLPPSQEE  MTKNQVSLTC  LVKGFYPSDI  AVEWESNGQP  ENNYKTTPPV  450
LDSDGSFFLY  SRLTVDKSRW  QEGNVFSCSV  MHEALHNHYT  QKSLSLSLG   499
```

Light chain X', X'''

```
EIVLTQSPGT  LSLSPGERAT  LSCRASQSVS  SSFLAWYQQK  PGQAPRLLIY   50'
GASSRATGIP  DRFSGSGSGT  DFTLTISRLE  PEDFAVYYCQ  QYGSSPWTFG  100'
QGTKVEIKGG  GSGGGGQVQL  VQSGAEVKKP  GASVKVSCKA  SGYSFTSYWM  150'
NWVRQAPGQG  LEWIGVIHPS  DSETWLDQKF  KDRVTITVDK  STSTAYMELS  200'
SLRSEDTAVY  YCAREHYGTS  PFAYWGQGTL  VTVSSGGCGG  GKVAACKEKV  250'
AALKEKVAAL  KEKVAALKE                                      269'
```

Disulfide bridges

23'-89'	23'''-89'''	23-92	23''-92''	138'-212'	138'''-212'''	141-215	141''-215''
240-238'	240''-238''	248-246'	248''-246'''	279-279''	282-282''	314-374	314''-374''
420-478	420''-478''						

Glycosylation sites (N)

350 350''

MOLECULAR FORMULA	$C_{7390}H_{11386}N_{1976}O_{2299}S_{52}$ (EXPASY)
MOLECULAR WEIGHT	166.4 kDa (EXPASY)
TRADEMARK	None as yet
SPONSOR	MacroGenics, Inc.
CODE DESIGNATIONS	MGD019, AEX1344
CAS REGISTRY NUMBER	2416595-46-3
UNII	JM802R57SA
WHO NUMBER	11771

gbk